Sign in
Taking peoplePhase 4

Gushen Antai Pill for women with infertility having embryo transfer after IVF

Tests Gushen Antai Pill in women with infertility undergoing fresh embryo transfer.

Key facts

Who runs it
Shandong University of Traditional Chinese Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET
Status
Recruiting
Phase
Phase 4
People taking part
800 people, planned
Started
15 Jun 2021
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Gushen Antai Pill
  • Placebo pill
Record updated
10 March 2026

Who can take part

The trial is looking for women with normal egg reserve having their first IVF or ICSI treatment with a fresh embryo transfer. It tests whether Gushen Antai Pill, added to vaginal progesterone, helps pregnancies continue.

Age
21 Years to 42 Years
Sex
Women only
Disease stage
Female infertility. Normal ovarian reserve, regular menstrual cycle (21-35 days) and normal ovulation. At least one embryo or blastocyst available for transfer.
Earlier treatment
This must be the first IVF / ICSI treatment. Women with two or more earlier failed IVF-ET attempts cannot join.
Biomarker or test result
AFC between 5 and 15, and AMH between 1.2 ng/ml and 3.5 ng/ml.
Main reasons for not taking part
  • Age 43 years or older, or BMI 28 Kg/m2 or higher
  • Polycystic ovary syndrome, chromosome (karyotype) abnormalities or abnormal shape of the womb
  • Two or more miscarriages in a row in the past
  • Freezing all embryos, natural or mild stimulation cycles, donated eggs, IVM, or embryo genetic testing (PGD, PGT-A)
  • Severe ovarian hyperstimulation syndrome, or health problems that make IVF or pregnancy unsafe
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Patients with normal ovarian function reserve (5 ≤ AFC ≤ 15, 1.2 ng/ml ≤ AMH ≤ 3.5 ng/ml)
  • Patients with regular menstrual cycle (21-35 days) and normal ovulation
  • Initial IVF / ICSI treatment
  • At least one embryo or blastocyst available for transfer

Who cannot take part

  • History of two or more previous consecutive spontaneous abortions
  • History of two or more previous IVF-ET failures
  • Presence of a non-surgically treated hydrosalpinx, uterine cavity fluid or endometrial polyp and an ovarian endometriosis cyst requiring surgery, during ovarian stimulation
  • Individuals with severe hyperstimulation ovarian syndrome during controlled ovarian stimulation
  • Polycystic ovary syndrome
  • Combined contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormalities of liver and kidney function, diabetes mellitus (glycosylated haemoglobin ≤7%, fasting blood glucose <10 mmol/L ), hypertension, thyroid disease, symptomatic heart disease, moderate to severe anaemia, history of malignancy or thromboembolism or propensity to thrombosis, severe psychiatric disorder, acute infections of the genitourinary system, sexually transmitted diseases, serious adverse habits such as drug abuse, exposure to teratogenic amounts of radiation, toxins, or drugs (such as prednisone or other hormones, adrenaline, antibiotics, or hypertension, cardiovascular, or antiviral medications) during the active procedure period , and uterine factor infertility or physical illness which prevents the ability to bear a pregnancy
  • Age ≥ 43 years old
  • Body mass index (BMI) ≥ 28 Kg/m2
  • "Freeze-all" strategy
  • Those using the natural cycle or mild stimulation for IVF/ICSI treatment
  • Acceptors of donated oocytes or performed either In vitro Maturation (IVM) or blastocyst biopsy for Preimplantation Genetic Diagnosis (PGD) or Preimplantation Genetic Testing for Aneuploidies (PGT-A)
  • Karyotype abnormalities
  • Congenital or acquired abnormalities of uterine anatomy

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Female infertility

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to investigate whether oral Gushen Antai pills supplementation for luteal phase support will improve ongoing pregnancy rate in women with normal ovarian reserve in fresh embryo transfer cycles.

The 2 groups in the trial

  • GSATP groupTreatment being tested

    Gushen Antai Pill (GSATP, 6g\* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.

    Treatment: Gushen Antai Pill

  • Placebo groupPlacebo, for comparison

    Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.

    Treatment: Placebo pill

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing in Vitro Fertilization Embryo Transfer: A Prospective, Multicentre, Randomised, Double-blind, Placebo-controlled Trial
Plain-language title
Gushen Antai Pill for women with infertility having embryo transfer after IVFGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT04872660, who can take part
Record updated
10 March 2026